Na Zhao
- Pharmaceutical Science top 2%
- Drug Solubulity and Delivery Systems 4
- Analytical Chemistry top 5%
- Analytical Methods in Pharmaceuticals 3
-
- Acute Myeloid Leukemia Research 6
- Platelet Disorders and Treatments 3
-
- Acute Lymphoblastic Leukemia research 3
-
- Bioactive Compounds and Antitumor Agents 2
-
- Natural product bioactivities and synthesis 2
- Retinoids in leukemia and cellular processes 2
- Co-authors
- Larry L. AugsburgerQi-Wen FanShaowen HuangFang ChenEncun DuChangcheng ZhengJintao WeiWei Zhang
- Partner nations
- ChinaUnited StatesDenmark
In The Last Decade
Na Zhao
26 papers receiving 481 citations
Peers
Comparison fields: 5 of 98
- Pharmaceutical Science 220
- Analytical Chemistry 75
- Complementary and alternative medicine 35
- Hematology 42
- Food Science 67
Countries citing papers authored by Na Zhao
This map shows the geographic impact of Na Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Zhao more than expected).
Fields of papers citing papers by Na Zhao
This network shows the impact of papers produced by Na Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Zhao. The network helps show where Na Zhao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Na Zhao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 10 | |
| 4 | 2025 | 0 | |
| 5 | 2025 | 2 | |
| 6 | 2025 | 0 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 0 | |
| 9 | 2023 | 12 | |
| 10 | 2023 | 6 | |
| 11 | 2023 | 2 | |
| 12 | Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study | 2022 | 1 |
| 13 | 2021 | 8 | |
| 14 | 2020 | 58 | |
| 15 | BHLHE41 promotes U87 and U251 cell proliferation via ERK/cyclinD1 signaling pathway | 2019 | 1 |
| 16 | 2019 | 44 | |
| 17 | 2016 | 10 | |
| 18 | 2006 | 43 | |
| 19 | 2005 | 108 | |
| 20 | 2005 | 117 |
About Na Zhao
Na Zhao is a scholar working on Hematology, Pharmaceutical Science and Toxicology, having authored 32 papers that have together received 519 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (6 papers), Drug Solubulity and Delivery Systems (4 papers), Analytical Methods in Pharmaceuticals (3 papers), Platelet Disorders and Treatments (3 papers), Acute Lymphoblastic Leukemia research (3 papers), Bioactive Compounds and Antitumor Agents (2 papers), Natural product bioactivities and synthesis (2 papers) and Retinoids in leukemia and cellular processes (2 papers). The work is most often cited by research in Pharmaceutical Science (220 citations), Analytical Chemistry (75 citations) and Complementary and alternative medicine (35 citations). Na Zhao has collaborated with scholars based in China, United States and Denmark. Frequent co-authors include Larry L. Augsburger, Qi-Wen Fan, Shaowen Huang, Fang Chen, Encun Du, Changcheng Zheng, Jintao Wei, Wei Zhang, Feng Jin and Li Zhou.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.